Concord Biotech Limited (CONCORDBIO.NS)

INR 1733.1

(4.79%)

Net Debt Summary of Concord Biotech Limited

  • Concord Biotech Limited's latest annual net debt in 2023 was -54.04 Million INR , down -119.27% from previous year.
  • Concord Biotech Limited's latest quarterly net debt in 2024 Q1 was 2.81 Billion INR , up 5311.68% from previous quarter.
  • Concord Biotech Limited reported annual net debt of 280.48 Million INR in 2022, down -54.63% from previous year.
  • Concord Biotech Limited reported annual net debt of 618.26 Million INR in 2021, down -26.52% from previous year.
  • Concord Biotech Limited reported quarterly net debt of -54.04 Million INR for 2023 Q4, down -102.4% from previous quarter.
  • Concord Biotech Limited reported quarterly net debt of -54.04 Million INR for 2023 FY, down -119.27% from previous quarter.

Annual Net Debt Chart of Concord Biotech Limited (2023 - 2019)

Historical Annual Net Debt of Concord Biotech Limited (2023 - 2019)

Year Net Debt Net Debt Growth
2023 -54.04 Million INR -119.27%
2022 280.48 Million INR -54.63%
2021 618.26 Million INR -26.52%
2020 841.39 Million INR 1474.75%
2019 53.43 Million INR 0.0%

Peer Net Debt Comparison of Concord Biotech Limited

Name Net Debt Net Debt Difference
Biocon Limited 140.18 Billion INR 100.039%
Blue Jet Healthcare Limited -830.93 Million INR 93.496%
Dishman Carbogen Amcis Limited 18.99 Billion INR 100.285%
Jubilant Ingrevia Limited 6.6 Billion INR 100.818%
Lyka Labs Limited 527.01 Million INR 110.255%
Panacea Biotec Limited -1.18 Billion INR 95.439%
Piramal Pharma Limited 42.27 Billion INR 100.128%
SMS Lifesciences India Limited 992.31 Million INR 105.446%
Supriya Lifescience Limited -694.68 Million INR 92.22%
Syngene International Limited -83 Million INR 34.886%
TAKE Solutions Limited 361.37 Million INR 114.956%
Zota Health Care Limited 942.79 Million INR 105.732%